Despite a plethora of clinical trials, no treatment has shown consistent success for symptomatic management in patients with chronic prostatitis–chronic pelvic pain syndrome. Subdividing this heterogeneous patient population according to phenotype, and selecting therapy accordingly, represents an important step forward in the treatment of this disorder.
